-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
During migraine attacks, mild pain at the time of the attack tends to escalate to moderate or severe pain
.
Phase III, open-label, dose-blinded 52-week extended trial
.
Compared with episodes treated with moderate or severe pain, the use of ubroepant during mild pain leads to a significantly higher pain-free rate, no associated symptoms, and normal function
is achieved two hours after administration.
This study provides class III evidence that ubroepant, 50 mg or 100 mg used by adults with mild migraine, increases the likelihood
of being free from migraine headache pain, migraine-related symptoms, and disability after 2 hours compared with moderate to severe migraine.
Source: Lipton RB, Dodick D, Goadsby PJ, et al.